近年,在类风湿关节炎(RA)早期诊断和治疗方面的变化主要在以下4个方面:抗环瓜氨酸肽(CCP)检测提高了RA诊断的特异性;更加积极使用口服缓解病情抗风湿药物(DMARDs)及生物制剂使大多数患者达到了疾病活动度的良好控制;对RA发病机制的进一步了解和新RA分类标准的发布使疾病的早期诊断和治疗成为现实;以及诸多对治疗反应及安全性的检测方法。 In recent years, the early diagnosis and treatment of rheumatoid arthritis (RA) changes mainly in the following four aspects: anti-cyclic citrullinated peptide (CCP) test increased the specificity of diagnosis of RA; more active use of oral anti-rheumatoid disease alleviate Drugs (DMARDs) and biologics have resulted in good control of disease activity in most patients; a better understanding of the pathogenesis of RA and the release of new RA criteria have made early diagnosis and treatment of the disease a reality; and many have been reported to respond to treatment and Safety testing methods.